Literature DB >> 10588772

Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole.

J Richter1, S Freise, R Mull, J C Millán.   

Abstract

Diagnosis of infection with the liver fluke Fasciola hepatica is usually difficult. Ultrasonography (US) might be a useful diagnostic alternative, and we assessed the value of sequential US in the diagnosis and monitoring of fascioliasis in 76 patients at baseline and for 60 days after treatment with triclabendazole. At baseline, biliary abnormalities were observed in 52 patients. Crescent-shaped parasites were seen in 11 patients; in 2 cases parasites were spontaneously moving and in 4 patients parasites were motionless. Postprandial examination revealed parasites adhering to the gallbladder wall in a further 5 cases. In 3 further cases, gallbladder contents were mobile but did not sediment downwards after patients changed position. Non-specific abnormalities were: impaired gallbladder contractility (n = 23), gallbladder tenderness (n = 19), debris (n = 6), calculi (n = 5), wall thickening (n = 2) and bile duct dilatation (n = 12). During day 1-7, Fasciola-like crescents in the gallbladder or passing through the bile duct were detected in another 15 patients, impaired gallbladder contractility in 16, gallbladder tenderness in 16, and bile duct dilatation in an additional 28 patients. Thirty-two patients with these US abnormalities experienced colic-like abdominal pain accompanied by increased alkaline phosphatase in 25 cases. During day 30-60, abnormalities regressed completely in 45 patients; 2/6 triclabendazole failures were evident by detection of living parasites. Biliary tract abnormalities are frequently observed by US, but the detection-rate of Fasciola hepatica is disappointingly low despite the parasite's relatively large size. US findings must therefore be interpreted together with other clinical measurements. The visualization of parasites being expelled through the dilated common bile duct allowed the causal interpretation of post-therapeutic abdominal pain and increase of liver enzymes. When triclabendazole is given on suspicion, visualization of worm expulsion and bile duct dilatation by US may be used to confirm diagnosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588772     DOI: 10.1046/j.1365-3156.1999.00482.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  5 in total

1.  Application of Ultrasonography in the Diagnosis of Infectious Diseases in Resource-Limited Settings.

Authors:  Enrico Brunetti; Tom Heller; Joachim Richter; Daniel Kaminstein; Daniel Youkee; Maria Teresa Giordani; Samuel Goblirsch; Francesca Tamarozzi
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

Review 2.  Ultrasonography of gallbladder abnormalities due to schistosomiasis.

Authors:  Joachim Richter; Daniel Azoulay; Yi Dong; Martha C Holtfreter; Robert Akpata; Julien Calderaro; Tarik El-Scheich; Matthias Breuer; Andreas Neumayr; Christoph Hatz; Gerald Kircheis; Monica C Botelho; Christoph F Dietrich
Journal:  Parasitol Res       Date:  2016-05-12       Impact factor: 2.289

3.  Diagnostic imaging in sheep hepatic fascioliasis: ultrasound, computer tomography and magnetic resonance findings.

Authors:  M Gonzalo-Orden; L Millán; M Alvarez; S Sánchez-Campos; R Jiménez; J González-Gallego; M J Tuñón
Journal:  Parasitol Res       Date:  2003-04-17       Impact factor: 2.289

4.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.

Authors:  David Richter; Joachim Richter; Beate Grüner; Kathrin Kranz; Juliane Franz; Peter Kern
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

5.  An incidental case of biliary fascioliasis with subtle clinical findings: US and MRCP findings.

Authors:  Hakan Onder; Faysal Ekici; Emin Adin; Suzan Kuday; Hatice Gümüş; Aslan Bilici
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.